0RG8 Stock Overview
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Sartorius Stedim Biotech S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €196.50 |
| 52 Week High | €287.60 |
| 52 Week Low | €160.10 |
| Beta | 0.59 |
| 1 Month Change | -29.77% |
| 3 Month Change | -11.78% |
| 1 Year Change | -23.16% |
| 3 Year Change | -48.69% |
| 5 Year Change | 62.67% |
| Change since IPO | 4,156.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RG8 | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | -21.7% | -8.6% | -0.9% |
| 1Y | -23.2% | -45.7% | -1.8% |
Return vs Industry: 0RG8 exceeded the UK Life Sciences industry which returned -45.7% over the past year.
Return vs Market: 0RG8 underperformed the UK Market which returned -1.8% over the past year.
Price Volatility
| 0RG8 volatility | |
|---|---|
| 0RG8 Average Weekly Movement | 6.6% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0RG8's share price has been volatile over the past 3 months.
Volatility Over Time: 0RG8's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 10,493 | Rene Faber | www.sartorius.com |
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products.
Sartorius Stedim Biotech S.A. Fundamentals Summary
| 0RG8 fundamental statistics | |
|---|---|
| Market cap | €19.12b |
| Earnings (TTM) | €254.70m |
| Revenue (TTM) | €2.72b |
75.1x
P/E Ratio7.0x
P/S RatioIs 0RG8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RG8 income statement (TTM) | |
|---|---|
| Revenue | €2.72b |
| Cost of Revenue | €1.53b |
| Gross Profit | €1.18b |
| Other Expenses | €927.00m |
| Earnings | €254.70m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 19, 2024
| Earnings per share (EPS) | 2.62 |
| Gross Margin | 43.50% |
| Net Profit Margin | 9.38% |
| Debt/Equity Ratio | 79.5% |
How did 0RG8 perform over the long term?
See historical performance and comparison